1
|
Hara N, Sawada Y. Epigenetics of Cutaneous T-Cell Lymphomas. Int J Mol Sci 2022; 23:ijms23073538. [PMID: 35408897 PMCID: PMC8998216 DOI: 10.3390/ijms23073538] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 03/16/2022] [Accepted: 03/23/2022] [Indexed: 02/05/2023] Open
Abstract
Epigenetic modifications rarely occur in isolation (as single “epigenetic modifications”). They usually appear together and form a network to control the epigenetic system. Cutaneous malignancies are usually affected by epigenetic changes. However, there is limited knowledge regarding the epigenetic changes associated with cutaneous lymphomas. In this review, we focused on cutaneous T-cell lymphomas such as mycosis fungoides, Sézary syndrome, and anaplastic large cell lymphoma. With regard to epigenetic changes, we summarize the detailed chemical modifications categorized into DNA methylation and histone acetylation and methylation. We also summarize the epigenetic modifications and characteristics of the drug for cutaneous T-cell lymphoma (CTCL). Furthermore, we discuss current research on epigenetic-targeted therapy against cutaneous T-cell lymphomas. Although the current method of treatment with histone deacetylase inhibitors does not exhibit sufficient therapeutic benefits in all cases of CTCL, epigenetic-targeted combination therapy might overcome this limitation for patients with CTCL.
Collapse
|
2
|
Uotila PM, Lemma SA, Haapasaari KM, Porvari K, Skarp S, Soini Y, Jantunen E, Turpeenniemi-Hujanen T, Kuittinen O. Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas. ACTA ACUST UNITED AC 2020; 25:241-246. [PMID: 32567520 DOI: 10.1080/16078454.2020.1780754] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
ABSTRACT Objectives: To investigate the protein expression of the epithelial-mesenchymal transition-inducing transcription factors (TFs) Twist, ZEB1 and Slug in peripheral T-cell lymphomas (PTCL) and their correlation with clinical parameters. Methods: The expression of these TFs was studied in 53 diagnostic biopsy specimens of several different PTCL subtypes with immunohistochemistry. Patient data were retrospectively collected from patient records and a statistical analysis was performed. Results: All three TFs were widely expressed. ZEB1 and Slug had correlations with clinical outcome. In all PTCL cases, high nuclear ZEB1 percentage correlated with a favorable progression-free survival (PFS) (3-year PFS: 70% vs. 34%; P = 0.010) and strong nuclear Slug intensity correlated with an unfavorable PFS (3-year PFS: 17% vs. 62%; P = 0.036). Discussion: The correlations between PFS and ZEB1 or Slug protein expression have not previously been established in PTCLs. The impact of ZEB1 and Slug expression on prognosis differed from our findings in DLBCL and the impact of ZEB1 expression was in line with current studies on mycosis fungoides and sézary syndrome. The findings may be explained by the roles these TFs play in hematopoiesis. Conclusion: ZEB1 and Slug may have potential clinical value for evaluating prognosis in PTCLs. The study size was small and heterogenous, and larger studies are warranted.
Collapse
Affiliation(s)
- Pyry M Uotila
- Department of Oncology and Radiotherapy, Oulu University Hospital and University of Oulu, Oulu, Finland.,Medical Research Center and Unit of Translational Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland
| | - Siria A Lemma
- Department of Oncology and Radiotherapy, Oulu University Hospital and University of Oulu, Oulu, Finland.,Medical Research Center and Unit of Translational Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland
| | | | - Katja Porvari
- Medical Research Center and Unit of Translational Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland.,Department of Pathology, Oulu University Hospital and University of Oulu, Oulu, Finland
| | - Sini Skarp
- Faculty of Biochemistry and Molecular Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland.,Biocenter Oulu, Oulu University, Oulu, Finland
| | - Ylermi Soini
- Department of Clinical Pathology and Forensic Medicine, Cancer Center of Eastern Finland, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland
| | - Esa Jantunen
- Department of Medicine, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland
| | - Taina Turpeenniemi-Hujanen
- Department of Oncology and Radiotherapy, Oulu University Hospital and University of Oulu, Oulu, Finland.,Medical Research Center and Unit of Translational Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland
| | - Outi Kuittinen
- Department of Oncology and Radiotherapy, Oulu University Hospital and University of Oulu, Oulu, Finland.,Medical Research Center and Unit of Translational Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland
| |
Collapse
|